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Abstract
Objective—To assess whether patients receiving aerobic exercise training performed either at home
or in a supervised group setting achieve reductions in depression comparable to standard
antidepressant medication (sertraline) and greater reductions in depression compared to placebo
controls.
Methods—Between October 2000 and November 2005, we performed a prospective, randomized
controlled trial (SMILE study) with allocation concealment and blinded outcome assessment in a
tertiary care teaching hospital. A total of 202 adults (153 women; 49 men) diagnosed with major
depression were assigned randomly to one of four conditions: supervised exercise in a group setting;
home-based exercise; antidepressant medication (sertraline, 50–200 mg daily); or placebo pill for 16
weeks. Patients underwent the structured clinical interview for depression and completed the
Hamilton Depression Rating Scale (HAM-D).
Results—After 4 months of treatment, 41% of the participants achieved remission, defined as no
longer meeting the criteria for major depressive disorder (MDD) and a HAM-D score of <8. Patients
receiving active treatments tended to have higher remission rates than the placebo controls:
supervised exercise = 45%; home-based exercise = 40%; medication = 47%; placebo = 31% (p = .
057). All treatment groups had lower HAM-D scores after treatment; scores for the active treatment
groups were not significantly different from the placebo group (p = .23).
Conclusions—The efficacy of exercise in patients seems generally comparable with patients
receiving antidepressant medication and both tend to be better than the placebo in patients with MDD.
Placebo response rates were high, suggesting that a considerable portion of the therapeutic response
is determined by patient expectations, ongoing symptom monitoring, attention, and other nonspecific
factors.
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Major depressive disorder (MDD) is a significant health problem with a lifetime prevalence
of 15% to 20% (1). MDD is associated with significant morbidity, mortality, disability, and
suffering for patients and their families (2,3), and ranks fourth among the leading causes of
disability-adjusted life-years worldwide (4). Projections for the year 2020 indicate that MDD
will be second only to coronary heart disease as a cause of illness burden worldwide (5).
Because no single treatment is effective for everyone (6,7), there has been great interest in the
development and evaluation of alternative therapies for MDD. Physical exercise is one such
therapy that has received considerable attention (8). A number of studies have shown that
aerobic exercise and resistance training may reduce self-reported depressive symptoms in
nonclinical populations (9-12) and in patients diagnosed with MDD (13-20). However, as noted
in previous reviews (8,21-24), many exercise studies have had a variety of methodological
limitations, including a lack of randomized designs, failure to assess adequately and document
cardiopulmonary training effects, unblinding of assessors, confounding of exercise with
psychotherapy, and inclusion of participants classified as “depressed” solely by self-reports of
symptom severity rather than by clinical interviews. In a meta-analysis evaluating 11
randomized controlled trials, Lawlor and Hopker (21) argued that because of these
methodological shortcomings, “the effectiveness of exercise in reducing symptoms of
depression cannot be determined because of a lack of good quality research on clinical
populations with adequate follow up.”
A previous study from our research group demonstrated that exercise was equally effective as
antidepressant medication in reducing depressive symptoms in 156 older patients with MDD
(13,25). However, because we did not include a no-treatment or placebo control group, we
could not rule out the possibility that the treatment benefits were due to the nonspecific effects
of staff attention and support that accompany involvement in a research study, or alternatively,
to the phenomenon of regression to the mean. In developing the current study protocol to
address this issue, the question was raised whether the information provided by a placebo
control condition is of significant scientific value to offset the possible negative consequences
of providing a “treatment” known to be of limited effectiveness. This ethical and scientific
dilemma has been a concern of our research team from the earliest stages of protocol
development. In our earlier study (13), the expectation was that an adequate assessment of the
efficacy of exercise therapy could be obtained through comparison with a standard medication
of proven efficacy. Subsequent critical reaction to our findings, however, demonstrated the
methodological weaknesses of this approach. Although we were able to show equivalent rates
of therapeutic response for exercise and antidepressant medication, experienced clinicians and
researchers viewed our results with skepticism because the data did not permit exclusion of
placebo response as accounting for the findings. This view is understandable, insofar as MDD
is a condition known to have a high and variable rate of placebo responsiveness, making it
essential that any innovative treatment be proven superior in effectiveness to placebo. As a
result of these considerations, we decided to incorporate a placebo pill condition into the present
design. Coupled with this decision, however, was an approach to safeguard the patients’ well-
being by establishing the eligibility criteria that would minimize their risk of participation,
closely monitoring patient symptoms and developing a plan for removing patients from the
trial if necessary. Our protocol was approved by the National Institutes of Health Review Panel
as well as our local Institutional Review Board.
In addition to the control group issue, because patients in our prior study exercised in a
supervised group, it is possible that social support from other patients may have contributed
to the observed reductions in depression. This issue also was a challenge in developing the
study design for our current protocol. Although we considered a “social support” control
condition, this intervention presumably also would be less effective, which raised the same
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ethical issues presented by a drug-placebo condition. We elected to control for the effects of
social support by comparing home-based exercise with supervised, group-based exercise. The
exercise prescriptions were identical, and the only difference between the groups was the
setting in which the exercise occurred.
A final issue that we considered in the development of the design of the present study concerns
the established treatment with which exercise would be compared. Antidepressant medications,
and specifically selective serotonin reuptake inhibitors (SSRIs), are common first-line
therapies. As in our prior study, we selected sertraline (Zoloft, Pfizer) as the standard treatment
for purposes of comparison because of its widespread usage and proven efficacy, tolerability,
and low toxicity (26). Remission, defined by the absence of MDD diagnosis and significant
reduction in depressive symptomatology (i.e., HAM-D score of <8) (27), was identified as the
goal of treatment (2,28); a better prognosis and higher levels of daily functioning accompany
remission as compared with the simple reduction of symptom severity (29,30). Thus, the
present study compared the effects of supervised group exercise, home-based individual
exercise, and an established antidepressant medication (sertraline) with placebo in a relatively
large sample of middle- aged and older adults diagnosed with MDD.
METHODS
This study was a randomized, parallel group, 16-week, placebo-controlled trial of exercise
(group-supervised and individual home-based), and sertraline treatment for MDD.
Participants
Outpatients were initially screened using the 21-item Beck Depression Inventory II (BDI)
(31). Participants obtaining a BDI score of ≥12 and subsequently meeting the Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for MDD (32) were
recruited between October 2000 and November 2005 through television, radio, and newspaper
advertisements. Eligibility criteria included age ≥40 years, presence of MDD, sedentary (i.e.,
no current involvement in regular exercise), and no current psychiatric treatment. Exclusion
criteria included the presence of another primary psychiatric diagnosis, such as a history of
bipolar disorder or psychosis; medical comorbidities that would preclude participation in the
trial (e.g., significant musculoskeletal difficulties); current use of antidepressants or other
psychotropic medications; dietary supplements or herbal therapies with purported
psychoactive indications; current active alcohol or drug abuse or dependence; and active
suicidal intent. All participants provided written informed consent and the protocol was
approved by the Institutional Review Board at Duke University Medical Center.
Assessment Procedures
Medical Screening—Before entry into the study, patients underwent a physical examination
by a study physician. Blood pressure was measured by standard sphygmomanometry in sitting
and standing positions. Patients were also given blood tests including routine electrolytes,
pregnancy and liver function tests, blood count, and thyroid stimulating hormone (TSH). If a
patient was found to have any significant medical condition that would contraindicate safe
participation in this study, he/she was excluded from participation in the study.
Depression Assessment—All potential patients were evaluated using the structured
clinical interview for depression (33) to diagnose MDD and the 17-item Hamilton Depression
Rating Scale (HAM-D) (34) to assess MDD severity at baseline and after 16 weeks.
Assessments were performed by licensed clinical psychologists blinded to the treatment
condition. To ensure patient safety and monitor symptom severity and suicidality, a trained
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research assistant administered the BDI by telephone weekly for the first 4 weeks and biweekly
for the subsequent 12 weeks.
Exercise Testing—Graded treadmill exercise testing was conducted before treatment and
at the conclusion of treatment to document the patients’ fitness levels and establish an exercise
training prescription for those patients subsequently randomized to exercise. Patients exercised
to exhaustion or other standard end points (e.g., chest pain, decreasing blood pressure, complex
premature ventricular contractions, progressive ST-segment depression) under continuous
electrocardiographic monitoring using the Duke-Wake Forest protocol in which workloads are
increased at a rate of 1 metabolic equivalent per minute (35). Expired air was collected by
mouthpiece for quantification of minute ventilation, oxygen consumption (VO2), and carbon
dioxide production (SensorMedics Metabolic Cart; Model 2900; Yorba Linda, California).
Samples were collected at 20-second intervals, and peak values were determined from an
average obtained during the last 60 seconds.
Treatment
Participants were assigned randomly in equal proportions to supervised aerobic exercise (n =
51), home-based aerobic exercise (n = 53), sertraline (n = 49), or placebo (n = 49).
Randomization was performed centrally by computer with conditional randomization
(stratified by age, gender, and depression severity); patients were provided with sealed
envelopes containing their group assignment.
Patients in the supervised aerobic exercise condition attended three supervised group exercise
sessions per week for 16 weeks. Based on maximum heart rate achieved during the treadmill
test, these patients were assigned training ranges equivalent to 70% to 85% maximum heart
rate reserve. Each aerobic session began with a 10-minute warm-up exercise of walking
followed by 30 minutes of walking or jogging on a treadmill at an intensity that would maintain
their heart rate within the assigned training range. The exercise session concluded with 5
minutes of cool-down exercises.
Participants in a home-based exercise program received the same exercise prescription but
exercised at home on their own with minimal contact from the study staff. Patients received
an initial home visit to establish their exercise training routine and they received instruction
about monitoring their exercise heart rates accurately. Home-based exercisers received
subsequent visits from an exercise physiologist after 1 month and 2 months, and telephone
calls at weeks 1 to 4 and biweekly thereafter until the end of the trial. Up to two additional
home visits were permitted if the patients reported difficulty adhering to the exercise
prescription. Three times during each exercise session, the participants in both exercise
conditions monitored and recorded their heart rates via radial pulses, along with ratings of
perceived exertion. Each week, home-based exercisers returned their exercise logs,
documenting exercise duration, intensity (heart rates), and ratings of perceived exertion.
Participants in the “pill” conditions were given the SSRIs, sertraline, or matching placebo
provided by Pfizer Inc. (New York, NY) by the treating psychiatrist (PMD). Medications were
provided once daily; the dosage depended on the clinical response, but usually each patient
received a starting dosage at 50 mg (one pill) of drug or placebo and received increasing dosages
to 200 mg (four pills)—contingent on therapeutic response and presence of side effects. The
treating psychiatrist was blinded to pill condition and used supportive measures to help manage
medication side effects. In cases of severe side effects or patient discomfort, the psychiatrist
could decrease the medication dosage at any time during the study. For insomnia, use of a
hypnotic (zolpidem) was limited to no more than four doses during treatment. Patients were
seen at the time of randomization and at weeks 2, 4, 8, 12, and 16.
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The treatment team and outcome assessors were unaware of the patients’ treatment
assignments, and only the research pharmacist was aware of which patients were assigned to
sertraline or placebo. The principal investigator and study coordinator, who were not involved
in the assessments or delivery of the interventions, were aware of whether patients were in pill
or exercise conditions. Pfizer provided sertraline tablets and placebo pills for use in this
research study, but they had no other role in the study design, data acquisition, data analysis,
or preparation of this manuscript.
Statistical Analysis—Treatment effects were evaluated using generalized linear models
with maximum likelihood estimation available in PROC GENMOD in SAS 9.1 (SAS Institute,
Cary, North Carolina). Our primary end point was remission, defined as no DSM diagnosis of
MDD and a HAM-D score of <8, and also as a continuous severity score on the HAM-D.
Treatment group, age, gender, race (Caucasian versus non-Caucasian), pretreatment HAM-D
score, and number of prior episodes of MDD were selected a priori as covariables. In the
generalized linear model, the binomial error distribution was assumed for the binary outcome,
and Gaussian errors were assumed for the HAM-D outcome.
Prior antidepressant drug trials have shown a high rate of placebo response (36,37), which
often takes the form of a clinically significant response (>50% reduction in symptoms) during
the first week of treatment. For this reason, we performed an exploratory analysis in which we
examined the subset of patients who did not show this early response. (In the present report,
the term “early responder” and not “placebo responder” is used to describe patients in any
treatment group—active as well as placebo—who exhibited a >50% reduction in self-reported
BDI scores within the first week after initiating treatment). Treatment effects for the primary
depression outcomes were estimated using three planned contrasts: all active treatment versus
placebo; the two exercise groups versus medication; and home-based versus supervised
exercise.
Analyses followed the intent-to-treat (ITT) principle (38), using the last observation carried
forward method. We also evaluated the extent to which models met assumptions, including
nonadditivity, linearity, outlying data points, and the distribution of residuals. With respect to
statistical power, assuming a recovery rate of 30% in the placebo group and a two-side test at
α = 0.05, we estimated that with the sample size (assuming ITT), for any given group
comparison, we would have a power of about 0.80 to detect a difference of 0.30 in the
proportion of patients classified as recovered using the criteria of no DSM-IV diagnosis and a
HAM-D score of <8. For the HAM-D, the power was 0.80 to detect about a 4-point difference
(i.e., a little over a half standard deviation (SD)) between any two groups.
RESULTS
We screened 457 patients; 135 did not meet the criteria for MDD, 47 withdrew consent, 40
had an excluding psychiatric comorbidity, and 33 were ruled out for other reasons, leaving 202
participants available for randomization. Figure 1 shows the patient flow from initial
recruitment screening to posttreatment assessment and analysis.
Patient Characteristics
The four treatment groups had similar demographic and clinical characteristics. The mean age
of participants was 53 years, the majority being Caucasian and female (Table 1). The treatment
groups were similar with respect to history of MDD, age, gender, and ethnicity. The mean ±
standard deviation (SD) HAM-D score for the sample was 17 ± 5; most patients were
considered mild to moderately depressed (HAM-D score of <23); 40% of the sample had a
history of recurrent depression.
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Adherence and Treatment Fidelity
Adherence to medication treatment was evaluated by pill count. The mean dose of medication
prescribed over the course of the study was similar for the sertraline and placebo groups (mean
= 2.3 pills for both groups). There were seven (14.3%) dropouts in the sertraline (s) condition
and 14 (28.6%) dropouts in the placebo (p) condition. Reasons for dropout included
dissatisfaction with group assignment (2s, 1p), adverse effects of medication (1s, 3p), logistical
difficulties in attending treatment (1s), dissatisfaction with progress in treatment (2s, 5p),
dissatisfaction with treatment program (1p), development of a new medical condition (2p), and
unknown reasons due to difficulties contacting patients (1s, 3p).
Patients met with a study psychiatrist for six visits including a baseline visit to initiate therapy,
four planned medication visits to adjust dosage at weeks 2, 4, 8, and 12, and a final visit at
week 16 to transition patients for further treatment if needed. Eighty-three per cent of patients
in the medication condition attended six visits compared with 72% of patients in the placebo
group (p = .481). Seven patients (3p, 4s) had an additional (i.e., seventh) visit with the study
psychiatrist to address issues related to side effects. Pill patients attended an average of 5.30
± 1.7 psychiatric visits; there was no statistically significant difference in attendance between
patients receiving sertraline (5.53 ± 1.4) and patients receiving placebo (5.06 ± 1.9; p = .16).
We employed a 5-point Likert “Treatment Belief” rating scale ranging from 1 (I am very sure
I am on placebo) to 5 (I am very sure I am on the active medication) to assess the patients’
beliefs about which pill they were receiving. At the end of treatment, 52% of patients receiving
sertraline thought that they had received the active drug, 38% were “unsure,” and only 10%
thought they were on placebo. In contrast, 37% of patients receiving the placebo thought that
they had received the active medication, 27% thought they were receiving the placebo, and
36% were “unsure.”
Self-reported exercise frequency was greater for patients in the home-based exercise condition
(median = 40; interquartile range = 29–48 sessions) compared with patient attendance in the
supervised exercise condition (median = 37; interquartile range = 15–41 sessions). This
difference can be partially attributed to differential dropout rates, with only 3 (6%) dropouts
in home exercise and 10 (20%) dropouts from supervised exercise (p = .002). Because the
participants were not considered dropouts unless they discontinued exercise for the remaining
duration of the study, it was easier for patients in the home-based exercise to remain in the
study by maintaining minimal involvement in the exercise program. If data from exercise
dropouts are excluded, the attendance rates were comparable for home-based (93.9%) and
supervised (82.9%) exercise; 68% of home exercisers completed at least 75% of the 48
scheduled sessions compared with 67% of supervised exercisers (p = .892). Reasons for 13
exercise dropouts (home-based = h; supervised = s) included development of medical
contraindication (1h), worsening MDD (1h), logistical difficulties in attending treatment (4s),
dissatisfaction with progress in treatment (1h, 2s), dissatisfaction with treatment program (2s),
noncompliance (1s), and an unknown reason due to difficulty contacting the patient (1s).
All patients monitored their radial pulses manually to document adherence to their exercise
prescriptions. Polar monitors (Polar Electro Incorporated, Woodbury, New York) were also
used to verify self-reported heart rates among home exercisers by objectively measuring heart
rates in a random sample of 26 home exercisers over 1 to 4 months of monitoring. Polar-derived
exercise heart rate recordings and self-reported heart rates were highly correlated (r = .97; p
< .001). During exercise sessions, home-based exercisers achieved or exceeded their prescribed
heart rates 65% of the time, whereas supervised exercisers were at or above their target heart
rates 77% of the time (p < .01).
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Changes in Aerobic Capacity After Treatment
Figure 2 shows the mean posttreatment aerobic capacity and exercise treadmill test duration
for each of the treatment groups, adjusting for pretreatment levels. The exercise groups
displayed significantly higher levels of aerobic capacity (peak VO2) compared with placebo
and medication pill conditions (p < .0001). Differences in aerobic capacity were also noted
between exercise treatment conditions, with supervised exercise participants achieving higher
levels of posttreatment aerobic capacity than did home-based exercisers. Similarly, patients in
the two exercise conditions exhibited greater treadmill times compared with patients who
received pills (p < .0001), with supervised exercisers attaining longer treadmill times than those
patients who exercised at home (p < .0001). Participants in home-based exercise showed an
improvement of 3.5% in peak VO2 and 7.5% in treadmill time; supervised exercise improved
by 8.3% in peak VO2 and 18.8% in treadmill time; the medication group showed a 0.8%
decrease in peak VO2 and 3.9% improvement in treadmill time; and the placebo group declined
by 4% in peak VO2 and 2.3% in treadmill time.
Depression Outcomes
Our primary end point was remission of MDD, defined as no longer meeting the criteria for
MDD and achieving a HAM-D rating of <8 (27). Figure 3 (left panel) displays the predicted
probabilities of having no depression diagnosis after treatment for each group, adjusted for
age, gender, race, number of prior MDD episodes, and pretreatment HAM-D scores. Planned
contrasts demonstrated that home-based exercise, supervised exercise, and medication tended
to achieve higher remission rates compared with placebo (p = .057); there were no statistically
significant differences between the exercise groups and antidepressant medication or between
home-based and supervised exercise. The unadjusted remission rates were: supervised exercise
= 45%; home-based exercise = 40%; medication = 47%; and placebo = 31%. The adjusted
odds ratio for remission comparing active treatment with placebo was 2.0 (95% CI = 0.97, 4.2).
Previous trials have documented a high placebo response rate in which participants exhibit
significant and rapid (<1 week) symptomatic improvement to placebo treatment (39). Rather
than using a placebo run-in, which we considered to be too costly and burdensome to patients,
we performed an exploratory examination of our data and observed that 14 patients (7%)
exhibited a >50% reduction in BDI scores after the first week of treatment: five (9%) patients
in home exercise; one (2%) patient in supervised exercise; four (8%) patients received
medication; and four (8%) patients received placebo. Five patients failed to complete the
interim BDI assessments at week 1 and data from week 2 were used; five patients failed to
complete the BDI at weeks 1 and 2 and could therefore not be defined with respect to early
response and therefore were excluded from this analysis. When we limited our analysis to the
183 patients who did not show an early response, contrasts from the general linear model
demonstrated that all active treatment groups had higher remission rates compared with placebo
(p = .022); the differences between the exercise groups and medication (p = .879) and the
differences between the two exercise groups from each other (p = .519) were not statistically
significant. The adjusted odds ratio for remission comparing active treatment with placebo was
2.6 (95% confidence interval (CI) = 1.1, 5.8). The unadjusted rates of remission were:
supervised exercise (46%); home-based exercise (38%); medication (44%); and placebo
controls (26%). There was no difference among the remission rates of the active treatments
(Figure 3, right panel).
Continuous HAM-D depression scores served as a second primary end point. All groups
showed a clinically and statistically significant decline (p < .0001) in HAM-D scores from
baseline to 16 weeks: supervised exercise: −7.2 (SD = 6.9); home-based exercise: −7.1 (SD =
6.9); medication: −6.1 (SD = 6.7); placebo: −6.1 (SD = 7.3). Although the observed
posttreatment HAM-D scores in the active treatments were lower than those in placebo, the
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difference did not reach statistical significance (p = .231) (Figure 4, left panel). After limiting
the sample to those who did not show an early response and adjusting for age, gender, race,
number of prior MDD episodes, and pretreatment HAM-D scores, the HAM-D scores for
exercise and medication treatments tended to be lower than the placebo (p = .123). There were
no differences between the exercise groups and medication (p = .514) or between the two
exercise groups (Figure 4, right panel) (p = .510).
The treatment by depression severity interaction was not significant, suggesting that the
treatments affected mildly and more severely depressed patients in a similar fashion.
Examination of the 78 patients who obtained baseline HAM-D scores of ≥18 demonstrated
that the remission rates showed a similar pattern as observed in the full sample: home-based
exercise = 30%, n = 6/20; supervised exercise = 44%, n = 8/18; medication = 39%, n = 7/18;
and placebo = 27%, n = 6/22 (p = .51). A similar pattern was observed for the HAM-D scores
at posttreatment adjusting for pretreatment scores: home-based exercise (n = 20) = 12.3;
supervised exercise (n = 18) = 9.8; medication (n = 18) = 11.8; and placebo (n = 22) = 12.9
(p = .45).
Side Effects
Untoward effects of each treatment were examined by obtaining patient ratings on a 36-item
somatic symptom checklist (e.g., headaches, dizziness, gas, constipation, thirst, muscle pain,
and soreness), on which symptoms were rated on a 5-point Likert scale ranging from 0 (never)
to 4 (almost always). Calculations were obtained from the number of participants who reported
that a symptom had worsened after treatment. Few patients reported a worsening of symptoms.
Among the 36 side effects assessed, only one showed a statistically significant group difference
(p = .03): 31% patients receiving sertraline reported worse posttreatment diarrhea and loose
stools compared with 21% in home-based exercise, 10% in supervised exercise, and 12% in
the placebo group.
DISCUSSION
These results confirm and extend previous findings that exercise is comparable to
antidepressant medication in the treatment of patients with MDD. In our previous study (13),
56% of patients receiving sertraline and 47% assigned to supervised exercise were in remission
after 4 months of treatment and all patients achieved significant and comparable reductions in
depressive symptoms. That study, however, did not include a placebo control group, in the
absence of which it could not be affirmed that the observed improvement was due to exercise
or medication and not to nonspecific factors such as time, staff attention, or positive
expectations. Klein (40) argued cogently that when comparing nonpharmacologic
interventions to antidepressant medications, investigators must include a pill-placebo to assure
that the patient sample studied is one that is responsive to medication beyond the effects of a
placebo. This perspective maintains that it is not adequate merely to compare a new intervention
to a Food and Drug Administration-approved and widely utilized antidepressant (e.g.,
sertraline), but that all such trials must include a pill-placebo condition. Walsh and Sysko
(41) made similar arguments and concluded that studies evaluating new treatments lack
scientific credibility if there is no placebo and the only evidence for treatment efficacy is a
response that is statistically indistinguishable from the response to an established medication.
Therefore, we considered it essential to include a placebo condition in our study design.
In the current study, both exercise and medication achieved higher remission rates compared
with placebo; 45% of MDD patients undergoing supervised exercise, 40% undergoing home-
based exercise, and 47% receiving medication were in remission after 16 weeks of treatment,
compared with only 31% receiving placebo. These remission rates are considered to be
clinically meaningful, especially because HAM-D scores of <8 are associated with low relapse
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rates (42). The odds ratio for patients receiving either medication or exercise compared with
placebo was 0.50, which represents a 50% reduction in the odds of remaining depressed after
16 weeks. The remission rates that were observed in the present study compare favorably with
other randomized placebo controlled psychopharmacology trials in patients with MDD, which
are typically 35% to 40% (43-45). Fourteen (7%) patients exhibited an “early response” defined
as a ≥50% reduction in self-reported (BDI) depressive symptoms after only the first week of
treatment. When these early responders were removed from the analysis, the differences
between active treatments and placebo became more pronounced: 46% of patients in supervised
exercise, 38% in home-based exercise, and 44% receiving sertraline were in remission after 4
months, compared with only 26% of the placebo controls.
Although placebo response rates in treatment studies of MDD are highly variable, the 31%
placebo response rate observed in the present study is consistent with previous studies that
have reported placebo response rates ranging from 30% to 50% (46-48). Our finding of no
difference in HAM-D scores in patients receiving sertraline and placebo also is consistent with
results of other randomized control trials such as the Sertraline Antidepressant Heart Attack
Randomized Trial (SADHART) (49) and the St. John’s Wort trial (50), which found that
reductions in depressive symptoms were comparable when analyzing data from all patients
randomized to placebo and sertraline conditions.
Our overall findings are generally consistent with several meta-analytic reviews that suggested
that exercise may be an effective treatment for depression (22-24). However, as noted by
Lawlor and Hopker (21), the methodological limitations of prior studies have made it
impossible to definitively conclude that exercise is efficacious for treating MDD. Our findings
also do not provide conclusive evidence for the value of exercise. To our knowledge, the present
study is the first to compare the independent effects of exercise and medication to a placebo
control group. However, the effect size (defined as the mean group difference divided by the
pooled sample SD before treatment) for the HAM-D outcome was rather modest—comparing
all active treatment versus placebo, the treatment effect was about 0.20 using ITT and 0.30
after eliminating early responders. One reason for the low effect size relative to other studies
may be due to the fact that we used a placebo group rather than a wait list control group. Because
expectations for improvement are greater among patients receiving placebo compared with
wait list controls, the difference between active treatments and control conditions is likely to
be smaller in studies in which there are credible no-treatment control conditions. In addition,
the close surveillance and support of placebo participants may have provided additional
therapeutic benefit, further reducing differences between the active treatments and placebo
controls.
Another factor contributing to the modest effect size in the present study was our use of ITT
as our primary analytic approach. We used the last observation carried forward method to
derive outcome effects from patients who drop out prematurely and do not undergo follow-up
assessments. Although this approach is a widely used method of analysis, differential dropout
rates can affect the results. Assuming that there is a general tendency for depressed patients to
feel progressively better over the course of treatment, this improvement would be minimized
when posttreatment levels of depressive symptoms are represented by observations taken at
earlier points (51). The fact that the dropout rate for supervised exercise (20%) was greater
than that for home-based exercise (6%) or sertraline (7%) makes it more difficult to compare
the relative effectiveness of the treatment groups in this study.
Another question we addressed in the present study was whether the beneficial effects of
exercise observed in our previous study could have been attributable to the social stimulation
and support provided by the group setting of the exercise intervention. Would the same benefit
be observed if patients engaged in the exercise regimen individually at home? A small,
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randomized, controlled trial (14) recently demonstrated that exercise was associated with
reduced depressive symptoms independent of group support. However, this conclusion is
weakened by the fact that only 53 of 80 patients actually completed the 12-week trial, including
5 of 13 no-treatment controls. The present sample included 202 patients with MDD, and all
randomized patients were included in the primary ITT analyses. Our findings showed that there
was no difference in remission rates between patients who exercised in a supervised group
setting and those who exercised on their own. Although the two groups showed similar rates
of compliance with the exercise prescription, the supervised exercisers tended to push
themselves more consistently into the target heart rate range, which probably accounts for why
this group performed better than the home exercisers on end-of-study assessments of aerobic
fitness. The present findings suggest that, for this patient population, supervised exercise yields
better outcomes than home exercise with respect to physical conditioning, but that both seem
equally effective in achieving remission of clinical depression. Some studies (52,53), but not
all (54), have reported that supervised exercise training results in larger improvements in
functional capacity compared with home-based exercise, and that greater energy expenditure
is associated with larger reductions in depressive symptoms (14). It should be noted, however,
that our study was not powered to detect the relatively small differences in depressive
symptoms that we observed between the two exercise conditions; it is therefore not possible
to be certain that home-based exercise is comparable with supervised exercise in reducing
depressive symptoms. Even with greater power, however, it is not clear that such differences
would be clinically meaningful.
The mechanisms responsible for exercise-related improvements in depression are not known.
Although our data suggest that social support was not necessarily critical to the therapeutic
benefit of exercise, a number of psychological factors have been proposed to explain the effect
that exercise has on depressed mood including increased self-efficacy, a sense of mastery,
positive thoughts, distraction from negative thoughts, and enhanced self-concept. A number
of biologic pathways also have been suggested including increased central norepinephrine
neurotransmission (55-57), alterations in the hypothalamo-pituitary-adrenocortical axis (58),
and increased secretion of amine metabolites as well as serotonin synthesis and metabolism
(59-62).
It also should be emphasized that the intent of our study was not to determine if exercise is
superior to sertraline. It is more difficult to distinguish between active therapies than it is to
find a difference between active therapies and placebo. To reliably detect the small differences
in depression as measured by the HAM-D or BDI scores, it is estimated that at a minimum of
300 patients per arm is required (63). Although our sample of 202 patients with MDD is, to
our knowledge, the largest single site exercise study of MDD yet conducted, it also is important
to recognize that our study was underpowered to detect small differences between the active
treatment groups. Our initial power analysis determined that we had enough power to detect
just over a half SD (d = 0.55) difference with 50 patients per cell, which translates into about
a 4-point difference on the HAM-D (depending on the estimate of the variance of the scores).
However, we observed only a little over a 1-point difference between active treatment and
placebo on the HAM-D. If we assume that this is a reasonable estimate of the population
treatment effect, we would have required 950 patients to detect a statistically significant
difference, and a 1-point difference is not clinically meaningful.
Because participants in this study represent patient volunteers, it is difficult to determine the
extent to which these findings may generalize to typical outpatients seeking treatment for
MDD. Zimmerman et al. (64) estimated that only one in seven patients seen in an outpatient
clinical setting would be eligible to participate in pharmacological clinical trials, suggesting
that the response rate could be lower for patients seeking treatment in outpatient psychiatric
settings than those observed in clinical trials. Also, patients who are actively suicidal or who
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have severe MDD are ineligible for most placebo-controlled trials in which a subgroup of
individuals essentially receive “no treatment” for several months. Our sample consisted
primarily of patients with mild depression; only 39% of our sample had moderate-severe
depression (HAM-D scores of ≥18), which may limit the generalizability of our findings.
However, the more severely depressed patients in our study showed the same pattern of results
as their less depressed counterparts, suggesting that exercise may be beneficial to patients with
moderately severe depression as well as mild depression. Finally, we note that most of the
participants in the present study enrolled with the hope that they would receive exercise
treatment for their depression. It is unknown to what extent this willingness to engage in
exercise therapy is shared by the general population of outpatients with MDD. Thus, although
these results are promising and suggest that patients receptive to exercise therapy can achieve
significant symptomatic relief comparable to established medical therapies, the clinical
application of exercise therapy and the long-term benefits of exercise need to be studied further.
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Flowchart of participant recruitment and retainment throughout the study. MDD = major
depressive disorder; ITT = intention-to-treat.
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Mean aerobic capacity and exercise tolerance after 16 weeks of treatment, adjusting for
pretreatment levels of outcome variable, age, gender, race, and past major depressive disorder.
Participants in the exercise conditions showed greater aerobic capacity (left panel) and exercise
tolerance (right panel) compared with patients in the medication or placebo conditions. Error
bars represent 95% confidence limits. Planned contrasts for aerobic capacity were as follows:
all exercise versus placebo, p = .0001; medication versus placebo, p = .420; all exercise versus
medication, p = .0001. For exercise tolerance, the contrast results were: all exercise versus
placebo, p = .0001; medication versus placebo, p = .410; all exercise versus medication, p = .
0001. VO2 = oxygen consumption; Sup = supervised exercise; Med = medication; Plac =
placebo.
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Predicted probability of remission, defined as no major depressive disorder diagnosis and
Hamilton Depression Rating Scale (HAM-D) score of <8 after treatment, using intention-to-
treat (left panel) and limited to patients who did not exhibit an early response (n = 183) (right
panel). Early responders are defined as patients with >50% reduction from baseline in Beck
Depression Inventory scores after the first week of treatment. Probability estimates are for a
patient with the most typical profile in the study: age 52 years, female, Caucasian, one prior
major depressive episode, and a baseline HAM-D score of 17. Error bars represent 95%
confidence limits. Planned contrasts using intention-to-treat yielded the following test results:
all active treatment versus placebo, p = .057; all exercise versus medication, p = .636;
supervised exercise versus home exercise, p = .666. After removing early responders, the
contrast results were: all active treatment versus placebo, p = .022; all exercise versus
medication, p = .879; supervised exercise versus home exercise, p = .519. Sup = supervised
exercise; Med = medication; Plac = placebo.
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Hamilton Depression Rating Scale (HAM-D) scores after 16 weeks of treatment using
intention-to-treat analysis (left panel) and limited to patients who did not exhibit an early
response (n = 183) (right panel). Probability estimates are for a patient with the most typical
profile in the study: age 52 years, female, Caucasian, one prior major depressive episode, and
a baseline HAM-D score of 17. Error bars represent 95% confidence limits. Planned contrasts
for the HAM-D using intention-to-treat analysis yielded the following test results: all active
treatment versus placebo, p = .231; all exercise versus medication, p = .574; supervised exercise
versus home exercise, p = .624. After removing early responders, the contrast results were: all
active treatment versus placebo, p = .123; all exercise versus medication, p = .514; supervised
exercise versus home exercise, p = .510. Sup = supervised exercise; Med = medication; Plac
= placebo.
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